Rhumbline Advisers Lowers Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Rhumbline Advisers cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 170,620 shares of the biopharmaceutical company’s stock after selling 4,126 shares during the quarter. Rhumbline Advisers’ holdings in Regeneron Pharmaceuticals were worth $121,538,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Trust Co. of Vermont grew its holdings in shares of Regeneron Pharmaceuticals by 8.3% during the third quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 12 shares in the last quarter. Nvwm LLC grew its holdings in Regeneron Pharmaceuticals by 1.4% in the third quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock valued at $1,039,000 after purchasing an additional 14 shares during the period. Moss Adams Wealth Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 3.6% in the third quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock valued at $456,000 after purchasing an additional 15 shares during the period. Westhampton Capital LLC grew its holdings in Regeneron Pharmaceuticals by 1.7% in the third quarter. Westhampton Capital LLC now owns 893 shares of the biopharmaceutical company’s stock valued at $939,000 after purchasing an additional 15 shares during the period. Finally, Howe & Rusling Inc. grew its holdings in Regeneron Pharmaceuticals by 3.4% in the third quarter. Howe & Rusling Inc. now owns 462 shares of the biopharmaceutical company’s stock valued at $486,000 after purchasing an additional 15 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 0.1 %

NASDAQ REGN opened at $673.60 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 4.46. The company has a market capitalization of $74.02 billion, a price-to-earnings ratio of 17.60, a price-to-earnings-growth ratio of 2.38 and a beta of 0.08. The company’s fifty day moving average price is $706.92 and its two-hundred day moving average price is $897.42.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the prior year, the firm posted $11.86 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.52%.

Analysts Set New Price Targets

REGN has been the subject of a number of recent analyst reports. Sanford C. Bernstein lowered their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 target price for the company. Wells Fargo & Company lowered their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. Bernstein Bank lowered their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Finally, Citigroup reduced their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.